Axsome Therapeutics Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 1 sell rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Axsome Therapeutics stock.
View analyst ratings for Axsome Therapeutics or view top-rated stocks.

Wall Street analysts have given Axsome Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Axsome Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Axsome Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Axsome Therapeutics.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) posted its earnings results on Tuesday, November, 10th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.01.
View Axsome Therapeutics' earnings history.

Axsome Therapeutics' stock was trading at $73.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AXSM shares have decreased by 8.5% and is now trading at $67.36.
View which stocks have been most impacted by COVID-19.

12 Wall Street analysts have issued 1 year target prices for Axsome Therapeutics' stock. Their forecasts range from $66.00 to $210.00. On average, they anticipate Axsome Therapeutics' share price to reach $146.80 in the next twelve months. This suggests a possible upside of 117.9% from the stock's current price.
View analysts' price targets for Axsome Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Axsome Therapeutics include Dr. Reddy's Laboratories (RDY), Ultragenyx Pharmaceutical (RARE), Jazz Pharmaceuticals (JAZZ), Zai Lab (ZLAB), Ascendis Pharma A/S (ASND), Arrowhead Pharmaceuticals (ARWR), ACADIA Pharmaceuticals (ACAD), United Therapeutics (UTHR), Ionis Pharmaceuticals (IONS), Schrödinger (SDGR), Sarepta Therapeutics (SRPT), GW Pharmaceuticals (GWPH), Evotec (EVTCY), Allakos (ALLK) and Atea Pharmaceuticals (AVIR).
View all of AXSM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

(AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Axsome Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.10%), Iridian Asset Management LLC CT (5.53%), Price T Rowe Associates Inc. MD (2.78%), Alethea Capital Management LLC (2.70%), Baker BROS. Advisors LP (2.09%) and Alliancebernstein L.P. (1.60%). Company insiders that own Axsome Therapeutics stock include Mark Coleman, Mark E Saad and Nick Pizzie.
View institutional ownership trends for Axsome Therapeutics.

AXSM stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Janus Henderson Group PLC, Northern Trust Corp, Nuveen Asset Management LLC, Acuta Capital Partners LLC, Price T Rowe Associates Inc. MD, Duality Advisers LP, and Oak Ridge Investments LLC.
View insider buying and selling activity for Axsome Therapeutics or view top insider-selling stocks.

AXSM stock was acquired by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors LTD., Iridian Asset Management LLC CT, Peregrine Capital Management LLC, Alliancebernstein L.P., New York State Common Retirement Fund, SG Americas Securities LLC, Sei Investments Co., and CWM LLC. Company insiders that have bought Axsome Therapeutics stock in the last two years include Mark Coleman, Mark E Saad, and Nick Pizzie.
View insider buying and selling activity for Axsome Therapeutics or or view top insider-buying stocks.

Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXSM stock can currently be purchased for approximately $67.36.

Axsome Therapeutics has a market capitalization of $2.52 billion. The company earns $-68,350,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis.

Axsome Therapeutics employs 53 workers across the globe.

The official website for Axsome Therapeutics is axsome.com.

Axsome Therapeutics is headquartered at 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038.

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The company can be reached via phone at 212-332-3241.